Bispecific Antibodies and Antibody Drug Conjugates: More Complex and Targeted Biologic Therapeutics
With the maturation of monoclonal antibodies (mAbs) based cancer immunotherapy drugs that target specific, actionable biomarkers, the biopharmaceutical industry has been developing more complex mAbs, such as bispecific antibodies and antibody drug conjugates. The Business Research Company projects the global monoclonal antibody market will exceed USD 170 billion by 2025 at a 12.9 percent CAGR….